Severe acute respiratory syndrome coronavirus (SARS-CoV) causes a respiratory disease with a mortality rate of 10%. A mouseadapted SARS-CoV (SARS-CoV-MA15) lacking the envelope (E) protein (rSARS-CoV-MA15-⌬E) is attenuated in vivo. To identify E protein regions and host responses that contribute to rSARS-CoV-MA15-⌬E attenuation, several mutants (rSARS-CoV-MA15-E*) containing point mutations or deletions in the amino-terminal or the carboxy-terminal regions of the E protein were generated. Amino acid substitutions in the amino terminus, or deletion of regions in the internal carboxy-terminal region of E protein, led to virus attenuation. Attenuated viruses induced minimal lung injury, diminished limited neutrophil influx, and increased CD4
C oronaviruses (CoVs) are responsible for a wide range of important veterinary and human diseases (1) . Severe acute respiratory syndrome (SARS) is caused by a coronavirus (SARSCoV) that emerged in Guangdong Province, China, causing the 2002-2003 epidemic, and infecting more than 8,000 individuals with a 10% mortality rate (1) (2) (3) (4) (5) . A novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), was isolated from the sputum of a man with pneumonia and renal failure in Jeddah, Saudi Arabia, in 2012 (6, 7). As of 21 November 2014, the WHO confirmed 909 MERS cases, in which 36% of patients died (8) . CoVs similar to SARS-CoV and MERS-CoV have been found in bats distributed across the world from which new zoonotic transmissions into human population could occur (9) (10) (11) (12) (13) (14) (15) . Therefore, understanding the virulence mechanisms of these pathogens and developing efficacious vaccines and therapies are of high importance.
SARS-CoV is an enveloped virus with a single-stranded, positive-sense, 29.7-kb RNA genome (16, 17) . The 5= two-thirds of the genome comprise two overlapping open reading frames, ORF 1a and ORF 1b, encoding two polyproteins, pp1a and pp1ab. In addition, SARS-CoV encodes a set of structural proteins present in all CoVs: spike (S), membrane (M), envelope (E), nucleocapsid (N), and accessory proteins 3a, 6, 7a, 7b, 8a, 8b, and 9b (18) .
SARS-CoV E protein is a small integral membrane protein of 76 amino acids. This protein contains a short hydrophilic amino terminus, a hydrophobic region, and a hydrophilic carboxy terminus (19) . The hydrophobic region forms one amphipathic ␣-helix that oligomerizes and displays ion channel activity (20) (21) (22) . E protein is present in small amounts within viral particles but is abundantly synthesized in infected cells (23) (24) (25) , where it localizes mainly in the endoplasmic reticulum Golgi intermediate compartment (ERGIC), participating in virus morphogenesis and budding (25) (26) (27) . SARS-CoV lacking the E gene (rSARS-CoV-⌬E) was attenuated in vivo (28, 29) and protected against challenge with virulent SARS-CoV (30) (31) (32) . The E protein is a virulence factor, regulating cell stress response and apoptosis and promoting inflammation (33) . SARS-CoV causes a respiratory illness characterized by acute lung injury (ALI), and its most severe pathological form is acute respiratory distress syndrome (ARDS). These pathological conditions are characterized by diffuse alveolar damage (DAD), pulmonary cellular infiltration, hyaline membrane formation, and edema accumulation, leading to hypoxemia and eventually to death (34) (35) (36) (37) . SARS-CoV infection induces migration to the lungs of immune cells, such as neutrophils and macrophages, which initiate and amplify the inflammatory response (38, 39) . Accordingly, the levels of several proinflammatory cytokines, including gamma interferon (IFN-␥), IFN-inducible protein 10 (IP-10)/CXCL10, monocyte chemoattractant protein 1 (MCP-1)/ CCL2, and several interleukins (IL-1␤, IL-6, IL-8, and IL-12), are elevated in the lungs and peripheral blood of SARS patients (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) . This exacerbated inflammatory process correlates with lung injury and a poor outcome. T cells are essential to resolve SARSCoV infections. T cell responses play a crucial role in SARS-CoV clearance and in protection from clinical disease (50) (51) (52) . Accordingly, one notable finding in human SARS, associated with an adverse outcome, was the rapid development of lymphopenia, with numbers of CD4 ϩ T cells more severely reduced than those of CD8 ϩ T cells during acute disease (38, (53) (54) (55) (56) . The SARS-CoV Urbani strain virus causes no significant disease in wild-type (wt) mice (57) . Passage through BALB/c mouse lungs resulted in a mouse-adapted virus (MA15 strain) (57) , which upon infection reproduced many aspects of the human disease, such as high virus titers, pathological changes in lungs, viremia, neutrophilia, and lethality (57) . We previously showed that rSARS-CoV-MA15-⌬E was attenuated in mice and that immunization with rSARS-CoV-MA15-⌬E completely protected young and aged BALB/c mice against challenge with a lethal dose of MA15 (32, 58) . Furthermore, we showed that SARS-CoV E protein ion channel activity promoted virus virulence and fitness (37) . To identify the E protein regions and the mechanisms leading to SARS-CoV-⌬E attenuation, several mouse-adapted virus mutants encoding amino acid substitutions in the amino terminal or small deletions located in the carboxy-terminal region of the E protein (rSARS-CoV-MA15-E*) were constructed. Amino acid substitutions in the amino terminal, or deletion of regions in the central carboxy-terminal region of E protein, resulted in virus attenuation, accompanied by reductions in lung inflammation, neutrophil influx into the lungs, and proinflammatory cytokine expression. Remarkably, the number of T cells was increased in the lungs of mice infected with the less pathogenic viruses, most probably contributing to their more rapid clearance. Importantly, the attenuated mutants protected against the challenge with the virulent wt virus.
MATERIALS AND METHODS
Cells. Vero E6, BHK, and Huh7.5.1 cells were kindly provided by E. Snijder (University of Leiden, The Netherlands), H. Laude (Unité de Virologie et Immunologie Molecularies, INRA, France), and R. Bartenschlager (Department of Molecular Virology, University of Heidelberg, Germany), respectively, and were propagated as described previously (28) . Viruses. Mouse-adapted SARS-CoV-MA15 (57) was a gift from Kanta Subbarao (National Institutes of Health, Bethesda, MD). Recombinant viruses were rescued from infectious cDNA clones generated in our laboratory (32, 58, 59) .
Mice. Specific-pathogen-free BALB/c mice were purchased from the National Cancer Institute at the age of 6 or 16 weeks or from Harlan Laboratories (Holland) at the age of 8 weeks and maintained for 8 additional weeks. All experiments involving SARS-CoV were conducted in biosafety level 3 laboratories in the animal care facility at the University of Iowa or at the Center for Animal Health Research (CISA-INIA, Spain), Construction of pBAC-SARS-CoV-MA15-E* plasmids. Mutant viruses (rSARS-CoV-MA15-E*) with amino acid substitutions in the aminoterminal region (rSARS-CoV-MA15-Mut 1) or with small deletions covering different regions of the carboxy terminus of the E protein (rSARS-CoV-MA15-⌬2, -⌬3, -⌬4, -⌬5, and -⌬6) were constructed using an infectious cDNA clone. cDNA encoding the genome of the SARS-CoV-MA15 strain was assembled in a bacterial artificial chromosome (BAC) (pBAC-SARS-CoV-MA15 plasmid) (32, 58) . DNA fragments containing nucleotides (nt) 26044 to 26779 of the SARS-CoV genome were generated by overlap extension PCR in the case of the carboxy-terminal mutants, using as the template the pBAC-SARS-CoV-MA15 plasmid and the primers indicated in Table 1 , and by gene synthesis (Bio Basic, Inc.) in the case of the amino-terminal mutant. This last fragment included four point mutations, generating four amino acid changes: S3A (TCA to GCA), V5L (GTT to CTT), T9A (ACA to GCA), and T11A (ACG to GCG). The final PCR products or the fragments generated by gene synthesis were digested with the enzymes BamHI and MfeI and cloned into the intermediate plasmid psl1190ϩBamHI/SacII SARS-CoV to generate plasmids psl1190ϩBamHI/SacII SARS-CoV-E* (psl1190-Mut 1, ⌬2, ⌬3, ⌬4, ⌬5, and ⌬6). Plasmid psl1190ϩBamHI/SacII SARS-CoV contains a fragment corresponding to nucleotides 26045 to 30091 of the SARS-CoV infectious cDNA clone (59) engineered into the psl1190 plasmid (Pharmacia) using unique BamHI and SacII restriction sites. Finally, these fragments were inserted into pBAC-SARS-CoV-MA15 to generate pBAC-SARS-CoV-MA15-E* plasmids. The viruses were rescued in BHK and Vero E6 cells as previously described (28) . Virus was cloned by three rounds of plaque purification.
rSARS-CoV-MA15-E* growth kinetics. Subconfluent monolayers (90% confluence) of Vero E6 or Huh7.5.1 cells were infected at a multiplicity of infection (MOI) of 0.001 with rSARS-CoV-MA15-E*, rSARSCoV-MA15-⌬E, or rSARS-CoV-MA15. Culture supernatants were collected at the indicated times postinfection, and titers were determined on Vero E6 cells as previously described (28) .
Indirect immunofluorescence microscopy. To detect viral E protein expression, Vero E6 cells were grown to 70% confluence on glass coverslips and infected with rSARS-CoV-MA15, rSARS-CoV-MA15-⌬E, and rSARS-CoV-MA15-E* at an MOI of 0.3. At 24 h postinfection (hpi), cells were fixed with 4% paraformaldehyde for 20 min at room temperature. After washing and permeabilization, primary antibody incubations were performed for 90 min at room temperature. Rabbit polyclonal antibody (Ab) specific for E protein (dilution of 1:500; kindly provided by Shen Shuo, Institute of Molecular and Cellular Biology, Singapore) and a mouse anti-ERGIC marker (dilution of 1:200; Alexis Biochemicals) were used. Secondary antibodies specific for rabbit or mice species conjugated to Alexa 488 (for detection of E protein) or Alexa 594 (for detection of ERGIC), respectively (dilution of 1:500; Invitrogen), were incubated for 45 min at room temperature. Nuclei were stained using 4=,6-diamidino-
FIG 4
Weight loss and survival rate of mice inoculated with rSARS-CoV-MA15-E* mutants. BALB/c mice were intranasally infected with 1 ϫ 10 5 PFU of each virus (n ϭ 5 mice). Animals were monitored daily for weight loss (A) and survival (B). Animals that lost more than 30% of their initial body weight were euthanized. Differences in weight loss between attenuated and virulent viruses were statistically significant (*, P Ͻ 0.05).
2-phenylindole (DAPI) (dilution of 1:200; Sigma), and slides were examined on a Leica SP5 confocal microscope (Leica Microsystems).
Specific infectivity of rSARS-CoV-MA15-E* mutants. Subconfluent monolayers (90% confluence) of Vero E6 cells were infected at an MOI of 0.3 with rSARS-CoV-MA15-E*, rSARS-CoV-MA15-⌬E, or rSARS-CoV-MA15. At 8 hpi, the culture medium was harvested and replaced with fresh medium supplemented with 2% fetal bovine serum (FBS). Culture supernatants were collected at 11 hpi ("nascent virus"), and virus titer was determined on Vero E6 cells. Viral RNA was isolated from 400 l of supernatants using a MagMAX viral RNA isolation kit (Life Technologies) according to the manufacturer's instructions, and genomic RNA was quantified by reverse transcription-quantitative PCR (RT-qPCR) analysis. cDNAs were generated using a high-capacity cDNA transcription kit (Applied Biosystems) and the reverse primer Q-SARS-2015-RS (5=-ATG GCGTCGACAAGACGTAAT-3=). The cDNAs were amplified by qPCR using SYBR green PCR master mix (Applied Biosystems) with forward primer Q-SARS-1931-VS (5=-ACCACTCAATTCCTGATTTGCA-3=) and Q-SARS-2015-RS. The ratio of infectious virus titer to genomic RNA represents the specific infectivity.
Cycloheximide chase to estimate the half-life of rSARS-CoV-MA15-E* mutants. Subconfluent monolayers (90% confluence) of Vero E6 cells were infected with the wt or rSARS-CoV-MA15-E* virus at an MOI of 0.3. At 12 hpi, the cells were treated with 200 g/ml cycloheximide (Sigma). Cells were harvested at 0, 2, 4, 6, and 8 h, and cell extracts were prepared as previously described (60) . Samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. In fact, E protein half-life measurements were obtained by calculating E protein relative mass normalized to actin mass for each time point.
Western blot analysis. Cell lysates were resolved by SDS-PAGE, transferred to a nitrocellulose membrane by wet immunotransfer, and processed for Western blotting. The blots were probed with a rabbit polyclonal Ab specific for E protein (dilution of 1:6,000; kindly provided by Shen Shuo, Institute of Molecular and Cellular Biology, Singapore), a monoclonal Ab specific for hemagglutinin (HA) tag (dilution of 1:1,000; Sigma), or an antibody specific for ␤-actin (dilution of 1:10,000; Abcam). Bound antibodies were detected with horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse antibodies (dilution of 1:30,000; Cappel) and the Immobilon Western chemiluminescent substrate (Millipore). The blots were quantitated by phosphorimaging. The half-life of each E protein mutant was calculated by plotting the signal intensity (ratio of band intensity).
Plasmids. The pcDNA3-E plasmid encoding SARS-CoV E protein was used as previously described (25) . To construct a pcDNA3 plasmid encoding the viral M protein fused to an HA tag (pcDNA3-HA-M), primers M-EcoRI-HA-VS (5=-GCGCGCGCGAATTCGCCGCCATGTACCC ATACGATGTTCCAGATTACGCTGCAGACAACGGTACTATTACCG TTGAG-3=, encoding an HA sequence) and M-XhoI-RS (5=-CGCGCTC GAGTTACTGTACTAGCAAAGCAATATTGTC-3=) were used. GAATTC and CTCGAG are the recognition sequences for EcoRI and XhoI, respectively. A DNA fragment encoding the SARS-CoV M protein was generated using as the template the plasmid pBAC-SARS-CoV-MA15. To generate pcDNA3 plasmids encoding the E protein with deletions (pcDNA3-E-⌬3), primers ⌬-EcoRI-VS (5=-GCGCGCGCGAATTCGCCGCCATGTA CTCATTCGTTTCGGAAGAAACAG-3=) and ⌬-XhoI-RS (5=-CGCGCTCGAGTTAGACCAGAAGATCAGGAACTCCTTCAGAA GAGTT-3=) were used to amplify the DNA fragment encoding the SARSCoV E deletion proteins using as the template plasmids pBAC-SARSCoV-MA15-E* with the appropriate deletion. After PCR, these DNA fragments were digested by restriction enzymes EcoRI and XhoI and cloned into pcDNA3-E. All expression plasmids were verified by sequencing.
Immunoprecipitation assay. Vero E6 cells were grown to 90% confluence and cotransfected with a plasmid encoding an N-terminal HAtagged M protein (pcDNA3-HA-M), combined with plasmids expressing the full-length E protein or E protein with small deletions (pcDNA3-E or pcDNA-E-⌬3). Cells cotransfected with the plasmid pcDNA3-HA-M and the empty plasmid pcDNA3, lacking the coding region of E protein, were used as controls. Twenty-four hours later, cell extracts were collected as previously described (60) . For immunoprecipitation assays, monoclonal anti-HA agarose-conjugated clone HA-7 (Sigma) was used by following the manufacturer's instructions. Briefly, 75 l of the anti-HA agarose conjugate was incubated with the cell extracts overnight at 4°C. Immune complexes were eluted using 20 l 2ϫ SDS sample buffer and heating at 95°C for 3 min. Analysis of precipitated complexes was carried out by SDS-PAGE and Western blotting.
Virus infection and titration in mice. BALB/c mice were anesthetized with isoflurane and intranasally inoculated with 1 ϫ 10 5 PFU of virus in 50 l of Dulbecco's modified Eagle's medium (DMEM). For protection experiments, mice were immunized intranasally with 6 ϫ 10 3 PFU of the attenuated viruses and then challenged with an intranasal inoculation of 1 ϫ 10 5 PFU of rSARS-CoV-MA15 at 21 days postimmunization. Mice were monitored daily for weight loss and mortality. SARS-CoV-MA15 titers were measured in Vero E6 cells as described above. Viral titers were expressed as PFU/g tissue.
Histopathologic examination of infected mouse lungs. Lungs were removed from infected mice, fixed in zinc formalin, and paraffin embedded. Sections were stained with hematoxylin and eosin.
RNA analysis by RT-qPCR. BALB/c mice were intranasally inoculated with 1 ϫ 10 5 PFU of the corresponding virus or DMEM, as a control. Lungs were removed and incubated in RNAlater (Ambion) at 4°C for 24 h, prior to freezing at Ϫ80°C. Total RNA was extracted using an RNeasy minikit (Qiagen). Reverse transcription (RT) reactions were performed at 37°C for 2 h using the high-capacity cDNA transcription kit (Applied Biosystems) to generate cDNAs. qPCRs were performed using TaqMan gene expression assays (Applied Biosystems) specific for murine genes ( Table 2) . Quantification was achieved using the 2 -⌬⌬CT method (61) . The data represent the average of duplicate measurements from three independent mice.
Microarray analysis. Lungs from infected mice were collected at 2 days postinfection (p.i.), and total RNA was extracted using an RNeasy minikit (Qiagen). Total RNA from three different lungs was independently hybridized for each transcriptomic comparison. A total of 200 ng of RNA was amplified using a one-color low-input Quick Amp labeling kit (Agilent Technologies) and further purified with an RNeasy minikit (Qiagen). Preparation of probes and hybridization were performed as described in One-Color Microarray-Based Gene Expression Analysis, version 6.5 (62) . Images were captured with an Agilent microarray scanner, and spots were quantified using feature extraction software (Agilent Tech- nologies). Background correction and normalization of expression data were performed using linear models for microarray data (LIMMA) (63) .
Microarray data analysis. Linear model methods were used for determining differentially expressed genes. Each probe was tested for changes in expression over replicates by using an empirical Bayes moderated t statistic (64) . To control the false discovery rate (FDR), P values were corrected by using the method of Benjamini and Hochberg (64) . The expected false discovery rate was controlled to be less than 5%. Genes were considered differentially expressed when the FDRs were Ͻ0.05 and fold changes were Ͼ2 or Ͻ-2.
Measurement of leukocytes in the mouse lungs. Sixteen-week-old BALB/c mice were infected as indicated above with 1 ϫ 10 5 PFU of each virus. Lungs were removed from mice at 4 days p.i., and cells were prepared as previously described (51) . The numbers of macrophages, neutrophils, and CD4 and CD8 T cells were determined as previously described (32, 58) .
Cytokine multiplex analysis. Lungs from infected mice were homogenized and nuclear, cytoplasmic, and extracellular proteins were extracted using a nuclear extract kit (Active Motif, Carlsbad, CA). Supernatant proteins (cytoplasmic and extracellular proteins) were diluted 1:5 in assay diluent (Millipore) prior to analysis. The expression of tumor necrosis factor (TNF), MCP-1/CCL2, KC/CXCL1, IL-5, IL-6, IL-13, IFN-␥, macrophage inflammatory protein 1␣ (MIP-1␣)/CCL3, and MIP-1␤/CCL4 was determined as previously described (58) .
Statistical analysis. Student's t test was used to analyze differences in mean values between groups. All results are expressed as means Ϯ standard errors of the means (SEM). P values of Ͻ0.05 were considered statistically significant.
Microarray data accession number. MIAME-compliant results of the microarrays have been deposited in the Gene Expression Omnibus database (GEO [National Center for Biotechnology Information], accession code GSE59185).
RESULTS
Generation, growth, and characterization of rSARS-CoV-MA15-E* viruses. To identify the E protein regions responsible for rSARS-CoV-⌬E attenuation, a set of mutant viruses (rSARSCoV-MA15-E*) were generated (Fig. 1A) . In rSARS-CoV-MA15-Mut 1, the E protein amino-terminal region was modified by introducing point mutations, instead of deleting amino acids, in order to maintain unaltered the primary sequence of the 3b protein, as 3b and E genes partially overlap. Sequential or partially overlapping small deletions of 6 to 12 amino acids were introduced in the carboxy-terminal region of E protein to generate rSARS-CoV-MA15-⌬2, -⌬3, -⌬4, -⌬5, and -⌬6. The engineered viruses were rescued in Vero E6 cells, cloned by three rounds of plaque purification, and sequenced to confirm the presence of the desired mutations. Mutant E* and wt proteins were similarly localized within infected cells as determined by immunofluorescence by using antibodies specific for the E protein ( Fig. 2 and data not shown). All the mutant E proteins partially colocalized with the ERGIC marker as previously observed for the full-length protein (25) . These data indicated that none of the regions deleted were essential for the subcellular localization of E protein and that E protein functions that were associated with its localization were not affected. SARS-CoV E protein promotes virus production since elimination of the E gene decreases virus growth from 10-to 100-fold, depending on the cell type (28) . To delimit E protein regions involved in SARS-CoV production, growth kinetics of rSARS-CoV-MA15-E* were analyzed in Vero E6 and Huh7.5.1-infected cells (Fig. 1B) . Maximum viral titers were observed at 48 to 72 hpi in Vero E6 cells and at 72 hpi in Huh7.5.1 cells, for all the viruses. Mut 1 and ⌬6 viruses reached peak titers (Ͼ10 7 PFU/ml) similar to those observed for rSARS-CoV-MA15 in both cell lines. In contrast, the ⌬3 and ⌬5 viruses grew to lower titers (around 10 6 and 10 5 PFU/ml in Vero E6 and Huh7.5.1 cells, respectively), similar to those observed for virus lacking full-length E protein (⌬E). The ⌬4 virus grew to titers intermediate between titers of the wt and ⌬E viruses, reaching titers close to 10 7 and 10 6 PFU/ml in Vero E6 and Huh7.5.1 cells, respectively. The ⌬2 virus showed the lowest titers (10 5 and 10 4 PFU/ml in Vero E6 and Huh7.5.1 cells, respectively). These data indicated that deletion of SARS-CoV E protein regions 2, 3, and 5 reduced virus growth to the same extent that the deletion of full-length E protein did, suggesting that these regions themselves were essential for E protein function. In a subsequent experiment, we studied the ⌬3 and ⌬5 viruses, because viruses grew to titers similar to those of rSARS-CoV-MA15-⌬E.
Stability of rSARS-CoV-MA15-E* mutants in cell cultures. Prior to analyzing the virulence of rSARS-CoV-MA15-E*, their stability in cell culture was examined. The viruses were passaged daily 8 times in Vero E6 cells, followed by sequencing of the distal third of the genome, encompassing the S gene to the 3= end. Only minor changes were detected in the viral sequences of one representative isolate, suggesting that these viruses were in general genetically stable, at least in tissue culture (Fig. 3) . To analyze whether the mutations that the viruses incorporate after growing them in tissue culture cells are compensatory mutations, growth kinetics of the original and passaged viruses were compared by infecting Vero E6 and Huh7.5.1 cells and analyzing virus titers at different times postinfection. No significant differences in the production of infectious viruses were observed among the passaged viruses and the original viruses (data not shown), suggesting that the mutations that the viruses incorporate after growing them in cell culture are not compensatory mutations.
Virulence of rSARS-CoV-MA15-E* mutants. It was previously shown that a SARS-CoV lacking the full-length E protein was fully attenuated in vivo (28, 29, 32, 58) . To evaluate the relevance of E protein regions in virus virulence, BALB/c mice were were independently infected with each of the rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5 and wt viruses, at an MOI of 0.3. At 8 hpi, the culture medium was harvested and replaced with fresh medium supplemented with 2% FBS. Cell supernatants were collected at 11 hpi ("nascent virus"), and the levels of genomic RNA and infectious virus titer were analyzed by RT-qPCR and plaque assay, respectively. The ratio of infectious virus titer (PFU/ml) to genomic RNA is depicted in the graph as percentage of specific infectivity. Means and standard deviations are shown (n ϭ 3 mice).
mock infected or infected with rSARS-CoV-MA15-E*, rSARSCoV-MA15-⌬E, and rSARS-CoV-MA15. Clinical disease and survival were evaluated for 10 days. Mice infected with the parental virus showed disease symptoms from 2 days p.i., reflected by lethargy and ruffled fur. These mice rapidly lost weight, and 80% of them died by day 6 (Fig. 4) . Animals infected with ⌬6 virus, carrying a deletion in the last segment of the E protein, lost weight and died in a fashion similar to those inoculated with the wildtype virus (Fig. 4) . In contrast, mice infected with ⌬2, ⌬3, ⌬5, and ⌬E viruses showed no signs of disease (data not shown), did not significantly lose weight, and uniformly survived (Fig. 4) . Mice infected with the Mut 1 and ⌬4 viruses lost 15% and 10% of their initial weight, respectively, but recovered from 3 days p.i., and all of them survived (Fig. 4) . These data showed that E protein regions 1 and 4 and especially 2, 3, and 5 were required to maintain the optimal replication or virulence of SARS-CoV.
rSARS-CoV-MA15-E* growth in vivo. To evaluate whether any of the E protein regions were required for optimal virus growth in vivo, BALB/c mice were infected with rSARS-CoV-MA15-E*, rSARS-CoV-MA15-⌬E, or rSARS-CoV-MA15, and viral titers in lungs were determined at 2 and 4 days p.i. (Fig. 5) . Peak titers were reached by all viruses at 2 days p.i. and decreased around 5-to 20-fold at 4 days p.i. in all cases. The parental virus showed the highest titers, 8 ϫ 10 7 PFU/g of lung tissue at day 2 and 5 ϫ 10 7 PFU/g at day 4. Titers were reduced when E protein was fully eliminated (10 6 PFU/g at day 2 and 5 ϫ 10 4 PFU/g at day 4), confirming that rSARS-CoV-MA15-⌬E replicated less robustly in mice. rSARS-CoV-MA15-⌬6 grew to 7 ϫ 10 7 PFU/g at 2 days p.i. and 10 7 PFU/g at 4 days p.i., similarly to the wt virus (Fig. 5 ), indicating that E protein carboxy terminus region 6 is the least relevant for optimal in vivo growth. The ⌬2 and ⌬5 viruses grew to titers similar to those observed for the ⌬E virus, or even lower. In contrast, the Mut 1, ⌬3, and ⌬4 viruses grew to intermediate titers (10 7 PFU/g and 10 6 PFU/g at days 2 and 4, respectively) in lungs. These results are similar to those observed in tissue culture cells and showed that especially regions 2 and 5 of SARS-CoV E protein are required for optimal virus growth.
Lung pathology in rSARS-CoV-MA15-E*-infected mice.
To analyze the mechanisms leading to rSARS-CoV-MA15-E* attenuation, macroscopic and microscopic changes in the lungs of infected mice were analyzed at 2 and 4 days p.i. (Fig. 6) . The lungs from animals infected with the wt or ⌬6 viruses but not ⌬E, Mut 1, ⌬2, ⌬3, ⌬4, and ⌬5 viruses were increased in volume and were dusky red. Profuse areas of hemorrhage and weight increase, possibly due to leukocyte infiltration and edema accumulation, were especially evident at 4 days p.i. (Fig. 6B and C) . In contrast, histological examination of lungs from ⌬E, Mut 1, ⌬2, ⌬3, ⌬4, and ⌬5 virus-infected mice revealed only a small amount of lung damage and cellular infiltration, whereas examination of lungs infected with wt or ⌬6 virus showed substantial lung damage characterized by peribronchial/perivascular inflammatory cell infiltration, edema, and thickening of the alveolar walls at 2 and 4 days p.i. (Fig. 6A) . These data demonstrated that E protein regions 1, 2, 3, 4, and 5 contribute to the lung damage induced after SARS-CoV infection.
Specific infectivity and half-life of rSARS-CoV-MA15-E* mutants. In order to investigate whether the different small dele- Vero E6 cells were cotransfected with a plasmid pcDNA3 encoding the N-terminal HA-tagged M protein, combined with plasmids expressing the E-wt protein or the E protein with a small deletion, E-⌬3. Cotransfections of a plasmid encoding HA-M protein and of a plasmid without E protein were used as controls. Cells were lysed and analyzed by Western blotting with specific antibodies for the E protein and HA (left) or subjected to immunoprecipitation with the monoclonal HA-specific antibody. The presence of E and M proteins was analyzed in the precipitated fractions using E-or HA-specific antibodies (right).
tions within the E protein altered virus-specific infectivity, the titers of extracellular rSARS-CoV-MA15-wt, -⌬E, -⌬3, and -⌬5 viruses were compared to the level of the corresponding extracellular genomic RNA. The specific infectivities of rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5 mutants were lower (21%, 11%, and 17%, respectively) than that of the wt virus (Fig. 7) . Thus, introducing small deletions or modifications within E protein decreases the infectivity of the particles, probably contributing to the lower titers observed for the rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5 mutants.
To analyze whether the small deletions introduced in the E protein changed its stability, cellular translation was inhibited with cycloheximide, and the degradation of E protein was analyzed by Western blotting. The half-lives of the E proteins encoded by the rSARS-CoV-MA15-⌬3 and -⌬5 virus mutants were longer (3.5 h and 3.6 h, respectively) than that of the wt E protein, which had a half-life of 2.4 h, in agreement with previous results (65) (Fig. 8) . The fact that wild-type E protein has a shorter half-life can be explained, because this protein is more abundantly expressed at early times compared to mutant proteins. These results suggest that the introduction of small deletions within the E protein modestly alter the stability of the protein.
Binding between E protein and M protein.
The interactions between SARS-CoV E and M proteins play an essential role in the viral particle assembly (66) (67) (68) . Based on this observation, and on the result showing that the rSARS-CoV-MA15-⌬3 and -⌬5 viruses grew to lower titers than those for wt virus in cell cultures, the interaction between the E-⌬3 deletion protein and the M protein was analyzed. To this end, an HA-tagged, full-length M protein and E-⌬3 deletion protein were coexpressed in Vero E6 cells by transient transfection, and coimmunoprecipitation experiments were performed. The E-wt and E-⌬3 proteins were specifically coimmunoprecipitated together with the M protein, using an antibody specific for the HA tag fused to the M protein (Fig. 9) . These results confirm that E and M proteins interacted in infected cells and indicated that the ⌬3 deletion introduced within the E protein did not significantly alter the binding of this protein to the M protein.
Immune cell responses in rSARS-CoV-MA15-E*-infected mice. SARS progression and disease outcomes are associated with a massive influx of inflammatory cells to the lungs and a poor T cell response (50, 51, 54, 69) . Leukocyte infiltrates in the lungs of mice infected with virulent rSARS-CoV-MA15-wt or representative attenuated mutants (rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5) were quantified and characterized by flow cytometry. Total leukocyte numbers were slightly increased in lung cell infiltrates of mice infected with the attenuated mutants (⌬E, ⌬3, and ⌬5 viruses), compared to those infected with the parental virulent virus (Fig.  10A ). Higher total and relative levels of macrophages were observed in lung infiltrates of the mice infected with the attenuated viruses than in those infected with rSARS-CoV-MA15 (Fig. 10B) . Interestingly, a decrease in the percentage and total number of neutrophils was observed in the mice infected with the attenuated viruses compared to those in rSARS-CoV-MA15-infected mice (Fig. 10C) . These data showed that the attenuation observed for mutant viruses (⌬E, ⌬3, and ⌬5 viruses) correlated with a decrease in neutrophil influx and an increase in macrophage influx into the lungs. Higher total and relative numbers of CD4 ϩ and CD8 ϩ T cells were present in the lungs of ⌬E, ⌬3, and ⌬5 virus-infected mice than in virulent rSARS-CoV-MA15-infected lungs ( Fig. 10D and E). All data analyzed were statistically significant, with the exception of total leukocyte, neutrophil, and CD4 ϩ numbers. These data suggested that mice infected with the attenuated viruses develop higher T cell responses than those infected with virulent SARS-CoV, most likely contributing to virus clearance and disease attenuation.
Effect of SARS-CoV-MA15-E* virus infection on host gene expression.
To analyze host responses responsible for the attenuation of the rSARS-CoV-MA15-E* mutants, the transcriptomes of rSARS-CoV-MA15-, rSARS-CoV-MA15-⌬E-, rSARSCoV-MA15-⌬3-, rSARS-CoV-MA15-⌬5-, and mock-infected lungs were compared, using mouse microarrays (Fig. 11A and Table 3 ). The genes differentially expressed during SARS-CoV infection (both up-and downregulated) in rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5 virus-infected mice, compared to wt-infected mice, were clustered using DAVID software (70) . The most statistically significant clusters were associated with the immune response, the response to wounding, the defense response, and the inflammatory response (Fig. 11B) . Based on their principal biological function, the genes downregulated in mice infected with the attenuated rSARS-CoV-MA15 mutants were involved mainly in inflammation (Fig. 11C) . Interestingly, this reduction correlated with relative increase in the expression of the Th2 genes, such as those encoding IL-4 and IL-13, in comparison to that in mice infected with the parental virus.
To validate and confirm the results obtained using microarrays, several genes involved in inflammatory responses were selected for RT-qPCR analysis, and their expression was tested at 2 and 4 days p.i. A clear reduction of all the proinflammatory cytokines analyzed (TNF, CCL2, CCL3, CCL4, CXCL1, CXCL2, CXCL10, IL-6, IL-12B, and IFN-␥) was observed in the lungs of mice infected with the ⌬E, ⌬3, and ⌬5 attenuated viruses, compared to that in wt-infected mouse lungs ( Fig. 11C and 12A and B). In contrast, the expression of the Th2 cytokines IL-4, IL-5, and IL-13 was upregulated in the lungs of mice infected with the ⌬E, ⌬3, and ⌬5 attenuated viruses, compared to those from rSARSCoV-MA15-infected mice ( Fig. 11C and 12A and B). All data analyzed were statistically significant with minor exceptions. These changes were specific, as the mRNA levels of rRNA 18S and transforming growth factor ␤ (TGF-␤), encoded by another gene involved in the anti-inflammatory response but regulated posttranscriptionally (71, 72) , were the same in all mice (Fig. 12B) .
To confirm that the mRNA levels correlated with protein accumulation, the levels of TNF, CCL2, CXCL1, IL-5, IL-6, IL-13, IFN-␥, CCL3, and CCL4 were evaluated in lung extracts from mice infected with the rSARS-CoV-MA15, ⌬3, ⌬5, and ⌬E viruses or mock infected, as a control. mRNA levels of these cytokines matched with their protein levels in the mouse lungs (Fig. 13) . All cytokine differences at the protein level were statistically significant, with minor exceptions in CCL3, CXCL1, and CCL4 cytokines. All together, these results indicated that the macroscopic and microscopic inflammation present in the lungs of infected mice correlated with overexpression of proinflammatory cytokines and downregulation of anti-inflammatory cytokines.
Immunization with the attenuated mutant viruses protects mice against challenge with SARS-CoV-MA15 virus. Live attenuated vaccines are considered most effective in their ability to induce a long-lived, balanced immune response. In order to determine whether the attenuated mutant viruses were good vaccine candidates, the induction of protection conferred by the attenuated viruses with point mutations or small deletions, against the challenge with virulent SARS-CoV-MA15, was studied. Groups of BALB/c mice were either mock immunized with PBS or immunized with the Mut 1, ⌬2, ⌬3, ⌬4, and ⌬5 attenuated viruses. At 21 days postimmunization, mice were challenged with rSARS-CoV-MA15, and weight loss and mortality were monitored for 14 days postchallenge (Fig. 14) . All the nonimmunized mice lost weight and died by day 7 after rSARS-CoV-MA15 challenge. In contrast, vaccination with the attenuated mutant viruses completely protected mice from the lethal dose of SARS-CoV-MA15, as they showed no weight loss and all survived. These data indicated that all attenuated mutant viruses effectively induced a high level of protection against lethal rSARS-CoV-MA15 challenge in mice. 
DISCUSSION
An extensive study using a collection of recombinant viruses was performed to analyze E protein regions and host responses that contributed to the virulence of SARS-CoV. Several mutants encoding small deletions or point mutations within E protein were engineered, in the context of mouse-adapted SARS-CoV-MA15 (57) . Point mutations in the amino-terminal region and small deletions in the internal carboxy-terminal region of E protein led to viruses with an attenuated phenotype, similarly to that obtained by deleting the whole E protein of SARS-CoV. Infection of mice with the rSARS-CoV-MA15-Mut 1, -⌬2, -⌬3, -⌬4, -⌬5, and -⌬E mutants led to decreased lung pathology compared to that of wtinfected mice and no mortality. Therefore, these regions are required for the virus to develop its full pathogenic potential. In contrast, virus lacking the 12 carboxy-terminal amino acids of E protein (⌬6 mutant) was fully virulent, reinforcing the idea that not all small deletions within the E protein were attenuating. The deletion within rSARS-CoV-MA15-⌬6 includes the PDZ-binding motif (PBM) (73, 74) , and we previously showed that a mutant lacking this region is attenuated (73) . One possible explanation for this apparent discrepancy is that the last 6 amino acids within the ⌬6 virus (YSRVKN; Fig. 1 ) form an alternative PBM that could restore the virulent phenotype of the virus, an aspect that is currently being explored in our laboratory. Deletion or mutation of E protein regions could in principle affect basic properties of the protein, such as its subcellular localization and half-life, which could broadly disturb its major functions within the cell. The cytoplasmic tail of SARS-CoV E protein was shown to contain a signal providing Golgi localization (75) . In addition, CoV E protein may impair protein trafficking depending of its half-life (65) . None of these aspects was significantly altered, as mutant E proteins colocalized mainly with ERGIC markers, as described for the wt protein (25) , and the half-life of E* protein mutants was slightly increased (1.5-fold) compared with that of the wt protein (65) . Furthermore, the interaction between E and M proteins necessary for virus morphogenesis (66-68) was preserved despite deleting the ⌬3 region. Thus, the E-⌬3 region of SARS-CoV E protein is not required to interact with M protein. In contrast, the specific infectivity of the different small deletions within the E protein was lower (6-fold) than that of the wt virus. These modifications in E protein possibly contributed to the reduced infectivity observed for E protein deletion mutants that exhibited an attenuated phenotype. However, these phenomena are not necessarily linked, because we previously demonstrated that recombinant viruses containing point mutations in the E protein that inhibited its ion channel activity or eliminated its PBM grew to titers similar to those of the parental virus in the lungs of the infected mice (37, 73) . Nevertheless, these viruses caused a reduction in lung inflammation and pathology and were attenuated (37, 73) . Therefore, E* protein mutants may decrease virus virulence by affecting specific host responses, independently of effects on virus replication. Interestingly, the patterns of gene expression in infected lungs revealed that proinflammatory genes, such as those encoding TNF, CCL2, CCL3, CCL4, CXCL1, CXCL2, CXCL10, IL-6, IL-12B, and IFN-␥, were downregulated in rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5-infected mice compared to in wt-infected mice, most probably contributing to viral attenuation. Notably, increased levels of proinflammatory cytokines such as TNF, IL-6, CXCL10, CCL2, IL-8, and IL-12, which play a major role in mediating and amplifying ALI/ARDS, were found in the blood and the lungs of SARS patients (40-45, 48, 76) . Furthermore, the expression of the Th2 cytokines IL-4, IL-5, and IL-13 was increased in the lungs of mice infected with the attenuated viruses compared to in those infected with the virulent wt virus, possibly contributing to a better outcome. In agreement with this finding, the expression of IL-13 was increased in asymptomatic young BALB/c mice infected with a mouse-adapted SARS-CoV, compared to aged infected mice with severe respiratory disease (77) . All these data strongly suggest that the lower proinflammatory cytokine expression and higher antiinflammatory cytokine levels observed after infection with the attenuated mutants could account for the diminished lung pathology and virus attenuation.
Neutrophils play a key role in the progression of ALI/ARDS, and SARS patients with adverse outcomes presented with neutrophilia and high neutrophil counts in the lungs (38, 54, 78, 79) . Similarly, massive neutrophil influx into the lungs contributed to disease after influenza A virus and respiratory syncytial virus (RSV) infections (80) (81) (82) (83) . This phenomenon was reproduced in mice infected with virulent SARS-CoV-MA15, whereas a significant reduction of neutrophils in the lungs of the mice infected with the attenuated mutants was observed. Accordingly, the expression of CXCL1 and CXCL2, key factors that induce the chemotaxis of neutrophils (84, 85) , was increased when the fulllength E protein was present during SARS-CoV infection.
An increase of macrophage numbers was observed in mice infected with the attenuated mutants, compared to those infected with the virulent wt virus. In addition to their role in immunity, macrophages maintain physiologic homeostasis and contribute to tissue repair (86, 87) . Therefore, an increase of these cells during infection could favor disease resolution. Together, these data indicate that an increase in neutrophil numbers in conjunction with a decrease in macrophage numbers in the lungs is associated with more severe SARS-CoV pathogenesis and that the deletion of E protein carboxy-terminal regions was responsible for these changes in the phenotype of infiltrating immune cells and virus attenuation during SARS-CoV infection.
T cells are important for viral clearance and for protection from disease in primary SARS-CoV infection (50) (51) (52) , and low T cell counts correlate with adverse outcomes in SARS patients (38, 53, 54, 56) . Interestingly, we have shown that in rSARS-CoV-MA15-⌬E, -⌬3, and -⌬5-infected mice, which do not show a significant disease, CD4 ϩ and CD8 ϩ T cell counts are higher than those found in mice infected with the parental virus, which show adverse outcomes after infection. We were unable to measure virus-specific T cell responses, because rSARS-CoV-infected mice die before a significant T cell response develops (Fig. 4) . Several anti-SARS-CoV vaccine candidates have been developed since 2003, but none has been approved for use in humans (88, 89) . Live attenuated vaccines are considered most effective compared to other types of vaccines, as they induce a long-lived, balanced immune response. Remarkably, the attenuated mutants generated in this work provided full protection after challenge with the virulent wt virus. These viruses express a complete repertoire of viral proteins, except for the small regions deleted or mutated in the E protein. Therefore, it is predicted that they will elicit both antibody and T cell responses directed against the virus. The major problems of using live attenuated vaccines are the possibility that the viruses may revert to virulence. To overcome this limitation, we are introducing additional attenuating mutations into the Nsp1 protein to generate a safer vaccine candidate. The Nsp1 gene was selected as a target because it is located at a very distant site from that of the E gene in the viral genome, making the generation of a virulent virus through single recombination events with circulating coronaviruses unlikely.
In summary, we have shown that changes in the amino terminal and internal carboxy-terminal regions of E protein led to stable attenuated SARS-CoV mutants. These mutants showed a slight reduction in their specific infectivity, maintained the same E protein subcellular localization, and slightly increased their half- life compared to the wild-type virus. Moreover, the ⌬3 deletion introduced within the E protein maintained the interaction between E and M proteins. SARS-CoV attenuation correlated with limited lung pathology, mediated by decreased proinflammatory cytokine expression, increased anti-inflammatory cytokine levels, and reduced neutrophil accumulation in the lungs. In addition, higher CD4 ϩ and CD8 ϩ T cell counts in mice infected with the attenuated mutants most likely contributed to better outcomes. These attenuated mutants fully protected mice from challenge with virulent virus. These studies are the basis for the rational design of SARS-CoV vaccine candidates.
